Anatara Lifesciences Ltd (ASX:ANR) is pleased to release its latest institutional roadshow presentation and market update that will be delivered to investors over the next two weeks by CEO & Chairman, Dr Mel Bridges and Co-Founder and Chief Scientific Officer, Dr Tracey Mynott.
MMJ PhytoTech Limited (ASX:MMJ) has raised A$4 million through the placement of 19,512,196 fully paid ordinary shares ("Placement") to institutional and sophisticated investors at $0.205 per share.
Following the United Nations General Assembly (UNGA) High-Level Meeting on Antimicrobial Resistance (AMR), Anatara Lifesciences (ASX:ANR) confirmed its commitment to fighting AMR, starting with the food chain. Anatara, which is developing therapeutics for gastrointestinal diseases in production animals and humans announced today it had submitted an application to register Detach(TM).
Anatara Lifesciences (ASX:ANR) is pleased to announce that it has lodged its application for approval to register Detach(TM) with the Australian Pesticides and Veterinary Medicines Authority (APVMA). Detach(TM) is a natural, non-antibiotic alternative for the control of diarrhoea in piglets.
MMJ PhytoTech Ltd (ASX:MMJ) Directors present their report on the Consolidated Entity ("Group") consisting of MMJ PhytoTech Limited ("MMJ" or the "Company") (formerly PhytoTech Medical Ltd) and the entities it controlled at the end of, or during, the year ended 30 June 2016.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to provide the latest Investor Presentation regarding MMJ Brands to List on TSX-V via RTO.
MMJ PhytoTech Ltd (ASX:MMJ) is pleased to advise that it is set to unlock significant value for shareholders through the spin out of its core cannabis subsidiaries, United Greeneries Holdings Ltd and Satipharm AG, on the TSX-V.
